Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Metoclopramide Hydrochloride 5mg/5ml Oral Solution

Active Ingredient:
metoclopramide hydrochloride
Rosemont Pharmaceuticals Limited See contact details
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 21 Oct 2022
1. Name of the medicinal product

Metoclopramide Hydrochloride 5mg/5ml Oral Solution

2. Qualitative and quantitative composition

Each 5ml of oral solution contains 5mg metoclopramide hydrochloride monohydrate.

Excipient(s) with known effect:

Methyl parahydroxybenzoate (E218) – 5mg/5ml

Propyl parahydroxybenzoate (E216) – 1mg/5ml

Sorbitol solution (non-crystallising) (E420) – 0.25ml/5ml

Propylene glycol (E1520) – 0.25ml/5ml

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Oral Solution

4. Clinical particulars
4.1 Therapeutic indications

Adult population

Metoclopramide is indicated in adults for:

- Prevention of delayed chemotherapy induced nausea and vomiting (CINV).

- Prevention of radiotherapy induced nausea and vomiting (RINV).

- Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting. Metoclopramide can be used in combination with oral analgesics to improve the absorption of analgesics in acute migraine.

Paediatric population

Metoclopramide is indicated in children (aged 1-18 years) for:

- Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option.

4.2 Posology and method of administration

Method of Administration.

For oral use.

Suitable for administration via nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tubes. For further instructions see section 6.6.


All indications (adult patients)

The recommended single dose is 10 mg, repeated up to three times daily.

The maximum recommended daily dose is 30 mg or 0.5 mg/kg body weight.

The maximum recommended treatment duration is 5 days.

Prevention of delayed chemotherapy induced nausea and vomiting (CINV) (paediatric patients aged 1-18 years)

The recommended dose is 0.1 to 0.15 mg/kg body weight, repeated up to three times daily by oral route. The maximum dose in 24 hours is 0.5 mg/kg body weight.

Dosing table


Body Weight



1-3 years

10-14 kg

1 mg (1ml)

Up to 3 times daily

3-5 years

15-19 kg

2 mg (2ml)

Up to 3 times daily

5-9 years

20-29 kg

2.5 mg (2.5ml)

Up to 3 times daily

9-18 years

30-60 kg

5 mg (5ml)

Up to 3 times daily

15-18 years

Over 60 kg

10 mg (10ml)

Up to 3 times daily

The maximum treatment duration is 5 days for prevention of delayed chemotherapy induced nausea and vomiting (CINV).

Method of administration:

A minimal interval of 6 hours between two administrations is to be respected, even in case of vomiting or rejection of the dose (see section 4.4).

Special population


In elderly patients a dose reduction should be considered, based on renal and hepatic function and overall frailty.

Renal impairment:

In patients with end stage renal disease (Creatinine clearance ≤ 15 ml/min), the daily dose should be reduced by 75%.

In patients with moderate to severe renal impairment (Creatinine clearance 15-60 ml/min), the dose should be reduced by 50% (see section 5.2).

Hepatic impairment:

In patients with severe hepatic impairment, the dose should be reduced by 50% (see section 5.2).

Paediatric population

Metoclopramide is contraindicated in children aged less than 1 year (see section 4.3).

4.3 Contraindications

- Hypersensitivity to metoclopramide hydrochloride or any of the excipients listed in section 6.1

- Patients hypersensitive to procaine and procainamide may show cross-sensitivity

- Metoclopramide should not be used during the first three to four days following operations such as pyloroplasty or gut anastomosis as vigorous muscular contractions may not help healing

- Gastrointestinal haemorrhage, mechanical obstruction or gastro-intestinal perforation for which the stimulation of gastrointestinal motility constitutes a risk

- Confirmed or suspected pheochromocytoma, due to the risk of severe hypertension episodes

- History of neuroleptic or metoclopramide-induced tardive dyskinesia

- Epilepsy (increased crises frequency and intensity)

- Parkinson's disease

- Combination with levodopa or dopaminergic agonists (see section 4.5)

- Known history of methaemoglobinaemia with metoclopramide, or of NADH cytochrome-b5 deficiency

- Use in children less than 1 year of age due to an increased risk of extrapyramidal disorders (see section 4.4).

4.4 Special warnings and precautions for use

If, despite treatment, vomiting persists, the patient must be re-assessed to exclude the possibility of an underlying disorder, i.e. cerebral irritation.

Care should be exercised when using metoclopramide in patients with a history of atopy (including asthma) or porphyria.

Patients receiving this drug for the disorders associated with delayed gastric emptying should be reviewed at an early stage for response to treatment.

Metoclopramide may cause elevation of serum prolactin levels.

Neurological Disorders

Extrapyramidal disorders may occur, particularly in children and young adults, and/or when high doses are used. These reactions occur usually at the beginning of the treatment and can occur after a single administration. Metoclopramide should be discontinued immediately in the event of extrapyramidal symptoms. These effects are generally completely reversible after treatment discontinuation, but may require a symptomatic treatment (benzodiazepines in children and/or anticholinergic anti-Parkinsonian medicinal products in adults).

The time interval of at least 6 hours specified in section 4.2 should be respected between each metoclopramide administration, even in case of vomiting and rejection of the dose, in order to avoid overdose.

Prolonged treatment with metoclopramide may cause tardive dyskinesia, potentially irreversible, especially in the elderly. Treatment should not exceed 3 months because of the risk of tardive dyskinesia (see section 4.8). Treatment must be discontinued if clinical signs of tardive dyskinesia appear.

Neuroleptic malignant syndrome has been reported with metoclopramide in combination with neuroleptics as well as with metoclopramide monotherapy (see section 4.8). Metoclopramide should be discontinued immediately in the event of symptoms of neuroleptic malignant syndrome and appropriate treatment should be initiated.

Special care should be exercised in patients with underlying neurological conditions and in patients being treated with other centrally-acting drugs (see section 4.3).

Symptoms of Parkinson's disease may also be exacerbated by metoclopramide.


Methaemoglobinemia which could be related to NADH cytochrome b5 reductase deficiency has been reported. In such cases, metoclopramide should be immediately and permanently discontinued and appropriate measures initiated (such as treatment with methylene blue).

Cardiac Disorders

There have been reports of serious cardiovascular undesirable effects including cases of circulatory collapse, severe bradycardia, cardiac arrest and QT prolongation following administration of metoclopramide by injection, particularly via the intravenous route (see section 4.8).

Special care should be taken when administering metoclopramide, particularly via the intravenous route to the elderly population, to patients with cardiac conduction disturbances (including QT prolongation), patients with uncorrected electrolyte imbalance, bradycardia and those taking other drugs known to prolong QT interval.

Intravenous doses should be administered as a slow bolus (at least over 3 minutes) in order to reduce the risk of adverse effects (e.g. hypotension, akathisia).

Renal and Hepatic Impairment

In patients with renal impairment or with severe hepatic impairment, a dose reduction is recommended (see section 4.2).

Excipient Warnings

• Methyl and propyl parahydroxybenzoates are contained in this product which may cause allergic reactions (possibly delayed).

• Sorbitol. This medicine contains 227.3mg sorbitol (E420) in each 5ml.

The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account. The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.

Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.

• Propylene glycol. This medicine contains 259mg propylene glycol (E1520) in each 5ml.

Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce adverse effects in children less than 5 years old.

While propylene glycol has not been shown to cause reproductive or development toxicity in animals or humans, it may reach the foetus and was found in milk. As a consequence, administration of propylene glycol to pregnant or lactating patients should be considered on a case by case basis.

Medical monitoring is required in patients with impaired renal or hepatic functions because various adverse events attributed to propylene glycol have been reported such as renal dysfunction (acute tubular necrosis), acute renal failure and liver dysfunction.

4.5 Interaction with other medicinal products and other forms of interaction

Contraindicated combination

Levodopa or dopaminergic agonists (including apomorphine, bromocriptine and pergolide) and metoclopramide have a mutual antagonism (see section 4.3).

Combination to be avoided

Alcohol potentiates the sedative effect of metoclopramide; concurrent use may also accelerate gastric emptying of alcohol and thus may promote the rate and extent of absorption from the small intestine.

Combination to be taken into account

Due to the prokinetic effect of metoclopramide, the absorption of certain drugs may be modified.

Anticholinergics and morphine derivatives

Anticholinergics and morphine derivatives may have both a mutual antagonism with metoclopramide on the digestive tract motility.

Central nervous system depressants (morphine derivatives, anxiolytics, sedative H1 antihistamines, sedative antidepressants, barbiturates, clonidine and related)

Sedative effects of Central Nervous System depressants and metoclopramide are potentiated.


Metoclopramide may have an additive effect with other neuroleptics on the occurrence of extrapyramidal disorders.

Serotonergic drugs

The use of metoclopramide with serotonergic drugs such as SSRIs may increase the risk of serotonin syndrome.


Metoclopramide may decrease digoxin bioavailability. Careful monitoring of digoxin plasma concentration is required.


Metoclopramide increases ciclosporin bioavailability (Cmax by 46% and exposure by 22%). Careful monitoring of ciclosporin plasma concentration is required. The clinical consequence is uncertain.

Mivacurium and suxamethonium

Metoclopramide injection may prolong the duration of neuromuscular block (through inhibition of plasma cholinesterase).

Strong CYP2D6 inhibitors

Metoclopramide exposure levels are increased when co-administered with strong CYP2D6 inhibitors such as fluoxetine and paroxetine. Although the clinical significance is uncertain, patients should be monitored for adverse reactions.

Extrapyramidal reaction causing drugs (such as phenothiazines and tetrabenazine)

Concurrent use with metoclopramide may increase the frequency and severity of extrapyramidal side effects. Care should be exercised in the event of co-administration of these drugs.


Concurrent use with metoclopramide may accelerate absorption of mexiletine.

Diagnostic interference

With Gonadorelin test, concurrent use with metoclopramide may blunt the response to gonaderelin by increasing serum prolactin concentrations. Concurrent metoclopramide therapy may increase aldosterone and serum prolactin levels.

Aspirin and paracetamol

The absorption of any concurrently administered oral drug may be modified by the effect of metoclopramide on gastric motility. Drugs known to be affected in this way include aspirin and paracetamol.


Metoclopramide may reduce plasma concentrations of atovaquone.

4.6 Fertility, pregnancy and lactation


A large amount of data on pregnant women (more than 1000 exposed outcomes) indicates neither malformative toxicity nor foetotoxicity. Metoclopramide can be used during pregnancy if clinically needed. Due to pharmacological properties (as with other neuroleptics), in case of metoclopramide administration at the end of pregnancy, extrapyramidal syndrome in newborn cannot be excluded. Metoclopramide should be avoided at the end of pregnancy. If metoclopramide is used, neonatal monitoring should be undertaken.


Metoclopramide is excreted in breast milk at low level. Adverse reactions in the breast-fed baby cannot be excluded. Therefore metoclopramide is not recommended during breastfeeding. Discontinuation of metoclopramide in breastfeeding women should be considered.

4.7 Effects on ability to drive and use machines

Metoclopramide may cause drowsiness, dizziness, dyskinesia and dystonias which can affect the vision and also interfere with the ability to drive and operate machinery.

4.8 Undesirable effects

Adverse reactions listed by System Organ Class. Frequencies are defined using the following convention: very common (1/10), common (1/100, <1/10), uncommon (1/1000, <1/100), rare (1/10000, <1/1000), very rare (<1/10000), not known (cannot be estimated from the available data).

System Organ Class


Adverse reactions

Blood and lymphatic system disorders

Not known

Methaemoglobinaemia, which could be related to NADH cytochrome b5 reductase deficiency, particularly in neonates (see section 4.4);

Sulfhaemoglobinaemia, mainly with concomitant administration of high doses of sulfur-releasing medicinal products

Cardiac disorders


Bradycardia, particularly with intravenous formulation

Not known

Cardiac arrest, occurring shortly after injectable use, and which can be subsequent to bradycardia (see section 4.4); Asystole; Atrioventricular block; Sinus arrest particularly with intravenous formulation; Electrocardiogram QT prolonged; Torsade de Pointes

Endocrine disorders*


Amenorrhoea; Hyperprolactinaemia



Not known


Gastrointestinal disorders




Constipation; Nausea; Unusual dryness of mouth

General disorders and administration site conditions




Oedema (including face oedema)

Immune system disorders



Not known

Anaphylactic reaction (including anaphylactic shock particularly with intravenous formulation)

Nervous system disorders

Very common



Extrapyramidal disorders (particularly in children and young adults and/or when the recommended dose is exceeded, even following administration of a single dose of the drug) (see section 4.4); Parkinsonism; Akathisia


Dystonia (including visual disturbances and oculogyric crisis); Dyskinesia; Depressed level of consciousness


Convulsion especially in epileptic patients; Dizziness ; Headache

Not known

Tardive dyskinesia which may be persistent, during or after prolonged treatment, particularly in elderly patients (see section 4.4); Neuroleptic malignant syndrome (see section 4.4)

Psychiatric disorders


Depression; Restlessness




Confusional state; Trouble sleeping; Unusual irritability

Respiratory, thoracic and mediastinal disorders

Not known

Dyspnoea may occur

Skin and subcutaneous tissue disorders


Skin rash; A small number of skin reactions such as urticaria and pruritus

Vascular disorder


Hypotension; particularly with intravenous formulation

Not known

Shock, Syncope after injectable use, Acute hypertension in patients with phaeochromocytoma (see section 4.3)

* Endocrine disorders during prolonged treatment in relation with hyperprolactinaemia (amenorrhoea, galactorrhoea, gynaecomastia).

The following reactions, sometimes associated, occur more frequently when high doses are used:

- Extrapyramidal symptoms: acute dystonia and dyskinesia, parkinsonian syndrome, akathisia, even following administration of a single dose of the medicinal product, particularly in children and young adults (see section 4.4).

- Drowsiness, decreased level of consciousness, confusion, hallucination.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose


Extrapyramidal Disorder (muscle spasms, especially of jaw, neck, back, shuffling walk, tic like (jerky) movements of head and face, trembling and shaking of hands), drowsiness, decreased level of consciousness, confusion, hallucination and cardio-respiratory arrest may occur.


In case of extrapyramidal symptoms related or not to overdose, the treatment is only symptomatic (benzodiazepines in children and/or anticholinergic anti-parkinsonian medicinal products in adults).

A symptomatic treatment and a continuous monitoring of the cardiovascular and respiratory functions should be carried out according to clinical status.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Metoclopramide is a dopaminergic blocker, acting as a delayed gastro-intestinal emptying adjunct and as a peristaltic stimulant. The exact mechanism of action is unknown; it is believed that metoclopramide inhibits gastric smooth muscle relaxation produced by dopamine thus enhancing cholinergic responses of the gastrointestinal smooth muscles. Accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. At the same time, this action is accompanied by relaxation of the upper small intestine, resulting in an improved co-ordination between the body and the antrum of the stomach and the upper small intestine. Decreases reflux into the oesophagus by increasing the resting pressure of the lower oesophageal sphincter and improves acid clearance from the oesophagus by increasing amplitude of oesophageal peristaltic contractions.

As an anti-emetic; the dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves.

Metoclopramide also stimulates prolactin secretion.

5.2 Pharmacokinetic properties

Animal studies have shown metoclopramide to bind to plasma protein (13% - 22%), especially plasma albumin. Biotransformation is by the hepatic route.

Metoclopramide has a half life of four to six hours. The onset of action, by oral route of administration, is from 30 to 60 minutes. The duration on action is 1 to 2 hours.

Elimination is by the renal route, approximately 85% of an oral dose appears in the urine as unchanged drug and as sulfate and glucuronide conjugates.

Renal impairment

The clearance of metoclopramide is reduced by up to 70% in patients with severe renal impairment, while the plasma elimination half-life is increased (approximately 10 hours for a creatinine clearance of 10-50 mL/minute and 15 hours for a creatinine clearance <10 mL/minute).

Hepatic impairment

In patients with cirrhosis of the liver, accumulation of metoclopramide has been observed, associated with a 50% reduction in plasma clearance.

5.3 Preclinical safety data

None stated

6. Pharmaceutical particulars
6.1 List of excipients

Methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), propylene glycol (E1520), sorbitol solution (non crystallising) (E420), glycerol (E422), citric acid monohydrate (E330), lime and lemon flavours, sodium citrate (E331) and purified water.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

1 month once opened

6.4 Special precautions for storage

Store below 25° C and protect from light.

6.5 Nature and contents of container


Amber Type III glass bottle




HDPE, EPE wadded, tamper evident, child resistant


Polypropylene body and purple HDPE plunger with a capacity of 10ml, graduated at each 1ml and intermediate marks every 0.5ml

Bottle adaptor:

Low density polyethylene

6.6 Special precautions for disposal and other handling

Keep out of the sight and reach of children.

Any unused product or waste material should be disposed of in accordance with local requirements.

Instructions for using the oral dosing syringe:

• Open the bottle: press the cap and turn it anticlockwise (Figure 1).

• Insert the syringe adaptor into the bottle neck (Figure 2).

• Take the syringe and put it in the adaptor opening (Figure 3).

• Turn the bottle upside down (Figure 4).

• Fill the syringe with a small amount of solution by pulling the piston down (Figure 4A). Then push the piston upward in order to remove any possible bubbles (Figure 4B). Finally, pull the piston down to the graduation mark corresponding to the quantity in millilitres (ml) prescribed by your doctor (Figure 4C).

• Turn the bottle the right way up (Figure 5A).

• Remove the syringe from the adaptor (Figure 5B).

• Put the end of the syringe into your mouth and push the piston slowly back in to take the medicine.

• Wash the syringe with water and let it dry before you use it again (Figure 6).

• Close the bottle with the plastic screw cap - leave the syringe adaptor in the bottle.



Instruction for administration via nasogastric (NG) or percutaneous endoscopic gastrostomy (PEG) tubes:

Ensure that the enteral feeding tube is free from obstruction before administration.

1. Flush the enteral tube with 5mL of water.

2. Administer the required dose of Metoclopramide Hydrochloride Oral Solution with a suitable measuring device.

3. Flush the enteral tube with 5mL of water.

This product has not been tested with latex NG or PEG tubes and therefore should not be used with tubes made from latex.

7. Marketing authorisation holder

Rosemont Pharmaceuticals Ltd

Rosemont House

Yorkdale Industrial Park

Braithwaite Street


LS11 9XE


8. Marketing authorisation number(s)

PL 00427/0117

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 1 July 1998

Date of Renewal: 15 June 2006

10. Date of revision of the text

18 October 2022

Rosemont Pharmaceuticals Limited
Company image
Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, Yorkshire, LS11 9XE
+44 (0)113 244 1400
+44 (0)113 245 3567
Customer Care direct line
+44 (0)800 919 312
Out of Hours Telephone
+44 (0)795 762 3515
Out of Hours contact
[email protected]